Last reviewed · How we verify

NCT06875024

The Effects of Intelligent Intervention Programs on Hospitalized Elderly People With Frailty.

Not yet recruiting NA Last updated 3 April 2025
What this trial tests

NA trial testing Intelligent intervention programs in Frailty in Older Adults in 156 participants. Not yet recruiting.

Timeline
15 April 2025
Primary endpoint
30 June 2026
31 December 2026

Quick facts

Lead sponsorNational Taipei University of Nursing and Health Sciences
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposehealth services research
Enrollment156
Start date15 April 2025
Primary completion30 June 2026
Estimated completion31 December 2026
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

National Taipei University of Nursing and Health Sciences

Who can join

65 and older, any sex, with Frailty in Older Adults. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: As the aging population grows, hospitalized elderly individuals with frailty have become a major concern. Frailty is a complex syndrome linked to aging, marked by dependency and vulnerability. Elderly patients often face chronic diseases, making them more susceptible to frailty. Studies show frailty prevalence in hospitalized elderly patients is 88.7%, and 75.3% among kidney disease patients. Frailty is associated with advanced age, female gender, low body mass index, comorbidities, and poor nutrition, increasing the risks of falls, hospitalization, and mortality. Frail kidney disease patients face worse outcomes. However, frailty is reversible with early intervention. Current treatments, based on comprehensive geriatric assessment (CGA), require significant resources. This study aims to explore frailty prevention and care through research and intervention development. Purpose: To explore the effectiveness of an intelligent intervention program in improving frailty among hospitalized elderly individuals. Methods: An experimental research design was adopted. A total of 156 hospitalized elderly patients with kidney disease who met the inclusion criteria were recruited through convenience sampling. Participants were randomly assigned to either the experimental group (n = 78) or the control group (n = 78). The experimental group received a 12-week intelligent intervention program, while the control group received routine care.Subsequently, data on frailty level, daily living function 30 days after discharge, and unexpected readmission rate 30 days after discharge will be collected by researchers and analyzed using SPSS 22.0, including chi-square tests, repeated measures ANOVA, and Generalized Estimating Equations (GEE) for intra-group and inter-group comparisons of each outcome variable. Expected research results: This study aims to understand the current status and influencing factors of frailty among hospitalized elderly patients with kidney disease and to develop an intelligent intervention program. The goal is to provide clinical nursing staff with a frailty care strategy for hospitalized patients, effectively reducing frailty among elderly inpatients, improving their daily functional ability after discharge, and decreasing hospital readmission rates. Condition or disease: frailty Intervention/treatment: intelligent intervention program

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Frailty in Older Adults

Currently open trials in the same condition.

Other National Taipei University of Nursing and Health Sciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06875024.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing